J Biol Regul Homeost Agents. 2019 Jan 18;33(1):1-6.

Interleukin-1 family cytokines and mast cells: activation and inhibition.

Gallenga CE1, Pandolfi F2, Caraffa A3, Kritas SK4, Ronconi G5, Toniato E6, Martinotti S6, Pio Conti 7.

Author information

1 Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Italy.
2 La Cattolica University, Rome, Italy.
3 School of Pharmacy, University of Camerino, Camerino, Italy.
4 Microbiology and Infectious Diseases, Aristotle University of Thessaloniki, Macedonia, Greece.
5 UOS Clinica dei Pazienti del Territorio, Policlinico Gemelli, Rome, Italy.
6 Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” of Chieti-Pescara, Chieti, Italy.
7 Department of Immunology Division, Postgraduate Medical School, University of Chieti-Pescara, Chieti, Italy.


Activated mast cells (MCs) secrete a number of compounds including pro-inflammatory and anti-inflammatory cytokines. MCs are a potential source of cytokines and chemokines which participate in allergic reactions and inflammation. MCs can be activated by IgE through its receptor FceRI, but also by Toll-like receptors and/or interleukin (IL)-1. MCs can be a target for both pro-inflammatory and anti-inflammatory cytokines. IL-1 activates MCs to release inflammatory chemical mediators, and cytokines/chemokines, an effect which can be potentially inhibited by IL-37. In addition, IL-36 is also a powerful cytokine with a pro-inflammatory activity. IL-38 binds IL-36R and inhibits the pro-inflammatory activity of IL-36, thus performing a therapeutic action. In this article we review the role of MCs in relation to pro-inflammatory and anti-inflammatory IL-1 family member cytokines and a possible therapeutic effect in inflammatory disorders.

Publication type

  • Editorial


You may also like...